Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.412 +0.042 (+1.25%)
Streaming Delayed Price Updated: 9:46 AM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Via Benzinga
Topics Stocks
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review. 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
Via Benzinga
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible." 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst
Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease. 
Via Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility
Despite market volatility, these stocks are seeing strong buys by insiders. 
Via Talk Markets
Topics Stocks / Equities
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
Via Benzinga
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc
Via Business Wire
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
3 Small-Cap Stocks That Are Ready to Rocket Higher
With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity 
Via MarketBeat
Topics Government
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health. 
Via Benzinga
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.